Brief: Hookipa To Present Complete Hb-200 Phase 1 Results

Hookipa Pharma

27/05/2022 24:44

May 26 (Reuters) - HOOKIPA Pharma Inc  HOOK.O :
    * HOOKIPA TO PRESENT COMPLETE HB-200 PHASE 1 RESULTS AND
RECOMMENDED PHASE 2 DOSE FOR HB-202/HB-201 FOR THE TREATMENT OF
ADVANCED HPV16+ CANCERS AT ASCO
    * HOOKIPA PHARMA INC - PHASE 1 DATA SHOW SINGLE-VECTOR
HB-201 AND
2-VECTOR HB-202/HB-201 WERE GENERALLY WELL TOLERATED
    * HOOKIPA PHARMA INC - PHASE 1 DATA SHOW SINGLE-VECTOR
HB-201 AND
2-VECTOR HB-202/HB-201 RAPIDLY INDUCED TUMOR-SPECIFIC T CELLS
    * HOOKIPA PHARMA- PHASE 1 DATA SHOW SINGLE-VECTOR HB-201 &
2-VECTOR HB-202/HB-201 SHOWED ANTI-TUMOR ACTIVITY IN 
PRE-TREATED HEAD,  NECK CANCER PATIENTS
    * HOOKIPA PHARMA - POSTER PRESENTATION TO INCLUDE DATA
SUPPORTING
RECOMMENDED PHASE 2 DOSE FOR ALTERNATING 2-VECTOR HB-202/HB-201

Source text for Eikon:  ID:nGNX3Y3QtW 
Further company coverage:  HOOK.O 

 ((Reuters.Briefs@thomsonreuters.com;))